Moderna applies for EU approval of updated COVID-19 vaccine
Joe Raedle
Moderna (NASDAQ:MRNA) said that it has submitted an application to the European Medicines Agency for approval of its updated COVID-19 vaccine. 
The biotech firm said that preliminary clinical testing has shown the updated vaccine is effective in generating an immune response against XBB variants of the virus. 
Moderna added that it expects the vaccine to be available in ample supply for the fall, pending EU regulatory approval. The company has also filed for US regulatory approval. 
More on Moderna:

Moderna says updated COVID vaccine will be ready for the fall
Moderna raised to Buy at UBS on underappreciated pipeline
Moderna files application with FDA for updated COVID shot
FDA advisors recommend updated COVID shots against XBB variants
Moderna's Weakness Is Your Opportunity
Moderna: Likely To Drop Further